Fabry Disease Treatment Landscape and Epidemiology Analysis !!

What is Fabry Disease?

Fabry Disease is caused due to the excessive buildup of a particular type of fat in the body cells called Globotriaosylceramide. Fabry Disease is usually an inherited disease, and the symptoms of Fabry Disease at an early age can affect the body parts. Fabry disease is a rare but fatal disease. The person affected by Fabry Disease is affected by don’t have enzymes to break down lipids or fat in the body. The fat then gets collected in the blood vessels and tissues, which can result in the risk of heart attack, stroke, and kidney failure. This inherited disease is passed from parents to the child and so on.


Fabry disease is a rare but fatal disease. The lipid storage in the body can result in life-threatening episodes. Males are more prone to inherit Fabry Disease than females. According to research, it was estimated that the life expectancy of the person affected by Fabry Disease is about 58 years. The symptoms of Fabry Disease include pain that spreads throughout the body known as Fabry Crisis, Gastrointestinal complications, Headaches, hearing impairment, Impaired sweating, and vertigo.


Fabry Diseases Epidemiology 


Till now we have discussed what is a Fabry disease? What are the signs and symptoms of Fabry Disease? Now we will discuss the epidemiology of the Fabry disease. As per DelveInsight analysis, it was estimated that Fabry Disease prevalence in the 7MM was estimated to be approximately 13K cases in the year 2020., with theUnited States accounting for the maximum number of cases. As per our estimates, males are more prone to Fabry disease as compared to females in the  United States. Fabry Disease epidemiology segmentation can be done based on the prevalent cases of Fabry Disease, Phenotype-specific cases of Fabry Disease, Gender-specific cases of Fabry Disease, and Age-specific cases of Fabry Disease.


Fabry Diseases Market Insights


In recent years, there are many factors that have been anticipated to fuel the Fabry Disease market in the upcoming years. Factors such as increasing Disease prevalence, currently marketed therapies, pipeline therapies with a new mechanism of action, and the expected launch of new potential therapies in the market will boost the Fabry Disease Market Size.


According to the DelevInsight, the Fabry Disease market size was valued at USD 1,195.3 million in the year 2020.


Fabry Disease Key Companies


Many key pharmaceutical companies are involved in the development of Fabry Disease Drugs in the upcoming years. The key companies such as - Protalix Biotherapeutics, Sanofi Genzyme, Idorsia Pharmaceuticals, Avrobio, Sangamo Therapeutics, Shire, Takeda, Amicus Therapeutics, Ozmosis Research Inc, CellGenTech, Inc, uniQure, Codexis, Canbridge, Eleva GmbH, MP6 therapeutics, Sigilon Therapeutics, 4D Molecular Therapeutics, and Freeline Therapeutics, are currently developing new Fabry Disease treatment therapies that are expected to be launch in the upcoming years which will serve as a major booster for Fabry Disease treatment market.


Way Ahead


The current Fabry Disease market is lacking many therapies apart from those working on the Enzymes Replacement Therapies. Enzymes Replacement Therapies (ERT) have delivered a potential outcome in the treatment of the Fabry Disease population. However, the Enzymes Therapy must be delivered continuously, which is a challenging part of the ERT as it requires repeated calculations. Despite the fact that ERT is tolerated well by the population, there are still improvements to be done.


To know more about our Competitive Services, Click here: Pharma Competitive Intelligence

https://www.delveinsight.com/consulting/competitive-intelligence-services

Comments

Post a Comment

Popular posts from this blog

The Great PD-1 Inhibitor Battle: OPDIVO vs. KEYTRUDA in Japan

Image
  Analyzing OPDIVO’s Pre-2022 Sales Decline and KEYTRUDA’s Market Ascendancy Before 2022, OPDIVO, developed by Bristol-Myers Squibb (BMS), faced a significant sales decline in Japan’s PD-1 inhibitor market. Despite its initial success, the PD-1 and PD-L1 inhibitors faced challenges from new competitors and evolving market dynamics. One key competitor was Merck's KEYTRUDA, which steadily gained market share due to its broader range of approved indications and successful clinical trial outcomes. KEYTRUDA’s market ascendancy was marked by its approval for various cancers, including melanoma, non-small cell lung cancer, and urothelial carcinoma, among others, making it a versatile choice for oncologists. How OPDIVO Outpaced KEYTRUDA in Japan’s Pharmaceutical Market In 2022, OPDIVO made a remarkable comeback, outpacing KEYTRUDA in Japan’s pharmaceutical market. This resurgence was driven by several strategic moves by BMS. The company expanded OPDIVO’s indications, securing approvals fo
Read more

A detailed analysis of Vascular Stents Market Trends, Growth Opportunities, Challenges, and Epidemiology Forecast

Image
A vascular surgeon places a stent, which is a hollow mesh tube that supports the blood vessel's walls permanently and prevents it from closing up again (restenosis). Some stents are drug-eluting, which means they release medicine over time to help prevent another blockage. The  Vascular Stents market is being driven by a growing geriatric population as well as an increase in the number of surgical operations. The  Vascular Stents Market report from DelveInsight provides an in-depth analysis of  Vascular Stents, as well as historical and forecasted market trends in the 7MM (the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some Key Highlights from the  Vascular Stents Market Report The artery is kept open by a stent, which is a small metal mesh tube. The two methods for opening clogged peripheral arteries are angioplasty and stent implantation. Vascular Stents market is segmented on the basis of Product type, By Applications and End-user. Some of the
Read more
Image
Obstructive Sleep Apnea Market Trends and Therapeutic Advancements !! Obstructive Sleep Apnea (OSA) is a common chronic sleep disorder, which is characterized by periodic narrowing and obstruction of the pharyngeal airway during sleep, leading to a complete or partial obstruction of the airway, results of which are apneas, hypopneas, or sometimes both. Obstructive sleep apnea is a chronic and permanent condition, through proper therapy and medications the condition can be cured. Almost every system in the body is affected by Obstructive Sleep Apnea, resulting in an increased incidence of hypertension, stroke, altered immune system, and cardiovascular disease.  Obstructive Sleep Apnea is caused when the throat muscles relax during sleep, which causes the tissue in the back of the throat to collapse and block the upper airway. Daytime sleepiness is one of the most common symptoms of Obstructive Sleep Apnea. People affected with Obstructive Apnea also complain of memory problems, headach
Read more